NuraLogix has launched a health measurement app in Singapore
Canadian health AI company Neurallogics has launched its mobile health measurement app in Singapore.
Anura uses proprietary transdermal optical imaging technology, which captures blood information from a person’s mouth via video camera. It can measure various important parameters including blood pressure, heart rate, stress level, cardiac workload and risk of heart attack and stroke.
Oral blood flow data is processed through the cloud where an AI engine called DeepAfex implements advanced signal processing and in-depth learning to predict physiological and psychological effects.
According to the company, the reading process takes only 30 seconds.
Partners with AI drug discovery firm Standigm Merck Korea
Standigm, an AI drug discovery company in South Korea, has signed a Memorandum of Understanding (MoU) with Mark Korea, a life sciences firm for AI-powered drug discovery research.
Based on a media release, the partnership involves adopting Standigm of Mark’s AI software SYNTHIA for composite synthesis.
Cynthia is a computer-aided retrosynthetic design tool that can quickly design synthetic pathways.
“Applying AI to the drug discovery process can dramatically reduce the time it takes for innovative drug candidates to discover and find ways to optimize synthesis,” said Sojeong Yun, CEO and co-founder of Standigm.
Late last year, the stand was officially at Partnership with Institut Pasteur Korea to create new anti-tuberculosis drug candidates through AI.
Nalagenetics gets CE mark for its pharmacogenomics software
Singapore-based biotechnology firm Nalagenetics has received a CE mark for its pharmacogenomics software.
The PGx Core module in its Nala Clinical Decision Support software goes with its Nala PGx Core (R) Pharmacogenomics testing kit, which genotypes lead pharmacogen.
According to a press release, both products are used together as a plug-and-play solution for labs with QPCR machines.
The qPCR testing kit can read 20 of the four known pharmacogenes, CYP2D6, CYP2C9, CYP2C19 and SLCO1B1, while the software can generate more than 170 drug-gene reports.
In recent years, the qPCR test has been widely adopted for the COVID-19 test.
“Pharmacogenomics testing is becoming increasingly ubiquitous around the world, requiring quality and robust equipment to support rapid adoption growth,” said Levana Sunny, CEO of Nalagenetics.